my takeaway from briefly skimming through the article was this...

my takeaway from briefly skimming through the article was this paragraph. Exciting times

Since the 1980s, CS1 (or bisantrene) has shown some response in clinical trials as an anthracene compound for many types of cancer (47, 48). Recently, CS1 has been found to have high therapeutic efficacy against acute myeloid leukemia cells (32). In line with these findings, in our study, CS1 suppressed cell proliferation, induced cell cycle arrest in G2/M phase and promoted cell apoptosis in HCT116 cells in vitro. Moreover, CS1 treatment also inhibited tumor growth with minimal toxicity in colon cancer mouse models. 5-FU is the most common chemotherapeutic for CRC (49). However, the clinical efficacy is decreased in 5-FU resistant cells (50). Here, CS1 suppressed HCT116-5FUR cell viability in a dose-dependent manner (50-3200 nM, p<0.05 from 400 nM). These data suggested that CS1 might serve as a single alternative agent or in combination to overcome the resistance of 5-FU based therapies for CRC.